利培酮与奋乃静治疗老年期痴呆精神症状的对照研究

A control study on risperidone and perphenazine in the treatment of psychiatric symptoms of senile dementia patients.

目的 比较利培酮与奋乃静治疗老年期痴呆患者精神症状的疗效、不良反应及对认知功能的影响。方法 将符合条件的60例老年期痴呆患者随机分为利培酮组和奋乃静组(各30例)。治疗8周。采用一般情况调查表(自编)、临床疗效评定量表(CGI)、阿尔茨海默病病理行为评分表(BEHAVE AD)、简易智力状态检查(MMSE)及药物不良反应量表(TESS)分别进行疗效、不良反应和认知功能评估。结果 两组临床总体疗效比较:有效率分别为86. 67%和83 .33%,无显著性差异(P>0 .05)。两组BEHAVE AD评分治疗前后比较均有非常显著差异(P<0. 05,P<0 .01),治疗结束后两组间BEHAVE AD评分无显著差异(P>0 .05)。治疗结束后MMSE评分利培酮组较奋乃静组高,有显著差异(t=2 .26,P<0 .05 )。两组不良反应发生率无显著性差异(χ2 =0 .28,P>0 .05)。结论 利培酮与奋乃静对老年期痴呆的精神症状疗效、不良反应相近,但对认知功能的影响优于奋乃静,故利培酮更适合于伴有精神症状的老年期痴呆患者的治疗。

Objective To compare the efficacy,side effects and cognitive impairment of risperidone and perphenazine in the treatment of psychiatric symptoms of senile dementia patients.Method 60 senile dementia patients were randomly divided into two groups receiving risperidone and perphenazine respectively for 8 weeks.They were all assessed by CGI,BEHAVE-AD,MMSE and TESS.Results After treatment,the total efficacious rate was 86.67% and 83.33%,showed no significant difference in two groups(P>0.05).The scores of BEHAVE-AD were both significantly decreased(P<0.01~0.05),there was no significant difference in two groups.After treatment the risperidone group were higher than the perphenazine group in the MMSE scores,the difference was significant(t=2.26,P<0.05).There was no significant difference of side effects between two groups (χ 2=0.28,P>0.05).Conclusion Risperidone and perphenazine have the same efficacy and side effects to the senile dementia patients,risperidone was not affecting the cognition function,risperidone is more suitable to the senile dementia patients with psychiatric symptoms.